Therapeutic properties of a new glutaminase-asparaginase preparation and the influence of the lactate dehydrogenase-elevating virus.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D001216:Asparagine / Q000097:blood; D001224:Aspartic Acid / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005971:Glutamates / Q000097:blood; D005972:Glutaminase / Q000627:therapeutic use*; D005973:Glutamine / Q000097:blood; D006207:Half-Life; D006863:Hydrogen-Ion Concentration; D007525:Isoelectric Focusing; D007770:L-Lactate Dehydrogenase; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D012328:RNA Viruses
D000970:Antineoplastic Agents; D005971:Glutamates; D005973:Glutamine; D001224:Aspartic Acid; D001216:Asparagine; D007770:L-Lactate Dehydrogenase; D001215:Asparaginase; D005972:Glutaminase